In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...
Read More
In a nutshell The study looked at whether oral relugolix (Orgovyx, Relumina) could be used to suppress testosterone in men with advanced prostate cancer compared to leuprolide (Lupron). This study showed that relugolix was associated with more rapid and effective suppression of testosterone levels when compared...
Read MoreIn a nutshell This study aims to examine the effectiveness of niraparib (Zejula) combined with hormone therapy and radiotherapy to treat patients with high-risk prostate cancer. The main outcome to be measured will be how long patients remain cancer-free. This study is recruiting in Philadelphia, PA. The details Prostate cancer occurs mostly...
Read MoreIn a nutshell This article investigated the safety and effectiveness of Lutetium-177 PSMA (LuPSMA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The authors concluded that LuPSMA is a safe and effective treatment option for these patients. Some background mCRPC is cancer which has spread from its original site...
Read MoreIn a nutshell This phase 2 trial will investigate the safety and effectiveness of nivolumab (Opdivo) in recurrent prostate cancer (PC). The main outcome will be disease control. This trial is recruiting at two locations in Boston, MA, US. The details Prostate cancer (PC) is a highly treatable cancer in men. Patients are usually...
Read MoreIn a nutshell This trial evaluates the effectiveness of using chemotherapy in combination with radium-223 (a type of internal radiotherapy). The main outcome to be measured is overall survival. This trial is taking place in the United States. The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...
Read MoreIn a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...
Read MoreThis study compared the outcome of low-dose rate brachytherapy (LDR-BT) and image-guided intensity-modulated radiotherapy (IG-IMRT) for different severities of localized prostate cancer. Five year survival rates will almost the same across both treatments. Five year biochemical failure free survival rates were higher for patients treated with LDR-BT...
Read MoreIn a nutshell The authors aimed to determine guidelines for the treatment of relapsing, metastatic, and hormone-resistant prostate cancer. Some background Metastatic prostate cancer (advanced cancer) is cancer that has spread outside of the prostate to other organs of the body, despite treatment. Hormone therapy is the standard...
Read MoreIn a nutshell This study examined the effect of androgen deprivation therapy (ADT) on the risk of cardiovascular events (such as stroke or heart attack) in men treated with radiation therapy. Researchers concluded that ADT use during or after radiation therapy increases the risk of cardiovascular events. Some background Radiation therapy is a...
Read MoreIn a nutshell This study examined evidence for the role of prostate surgery in treating high-risk prostate cancer. Authors concluded that surgery is an effective primary treatment option for men with high-risk disease. Some background Localized prostate cancer is cancer that is confined to the prostate gland. Men with high-risk localized prostate...
Read MoreIn a nutshell This study examined whether immunotherapy with sipuleucel-T (Provenge) shows a greater immune response if administered before or after androgen deprivation therapy (ADT). Authors present preliminary evidence of improved immune cell response when sipuleucel-T was administered first in patients with recurrent prostate cancer at high risk of...
Read More
